Eli Lilly (LLY) announced on Thursday that a late-stage trial for its next-gen weight loss therapy, retatrutide, reached the primary and all secondary endpoints in adults with type 2 diabetes. Citing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results